Inventor · disambiguated record
Antonio Christian Ferretti
Also filed as: FERRETTI ANTONIO C · FERRETTI ANTONIO CHRISTIAN
12 granted patents·5 pending applications·12 citations·filing 2014–2025
85Inventor score
Top patents by PatentIndex Score
17 records- 0191US10189808B2Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2017·Granted Jan 29, 2019·10 cites·10 claims
- 0282US2025340536A1Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2025·Application pending·0 cites
- 0375US2023212137A1Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2022·Application pending·0 cites
- 0472US12391672B2Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2022·Granted Aug 19, 2025·0 cites·7 claims
- 0571US10517873B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2019·Granted Dec 31, 2019·0 cites·3 claims
- 0671US9604939B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2014·Granted Mar 28, 2017·1 cites·10 claims
- 0770US10005760B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2015·Granted Jun 26, 2018·1 cites·21 claims
- 0869US11401257B2Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2020·Granted Aug 2, 2022·0 cites·8 claims
- 0966US2023128975A1Process for the preparation of bromodomain inhibitorCELGENE QUANTICEL RES INC·Filed 2022·Application pending·0 cites
- 1062US11370777B2Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2020·Granted Jun 28, 2022·0 cites·28 claims
- 1159US10604510B2Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereofCELGENE CORP·Filed 2019·Granted Mar 31, 2020·0 cites·13 claims
- 1259US10202364B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 12, 2019·0 cites·16 claims
- 1359US9974786B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted May 22, 2018·0 cites·18 claims
- 1458US9795603B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Oct 24, 2017·0 cites·18 claims
- 1556US11566004B2Process for the preparation of bromodomain inhibitorCELGENE QUANTICEL RES INC·Filed 2019·Granted Jan 31, 2023·0 cites·17 claims
- 1649US2019100512A1Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereofCELGENE CORP·Filed 2015·Application pending·0 cites
- 1747US2024228475A1Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →